CVS Health delivered the kind of quarter that makes guidance look conservative. Adjusted EPS of $2.09 beat the $1.62 consensus by 15.5% and cleared the $1.81 Earnings Whisper number. Adjusted earnings grew 30.6% year over year. Revenue of $108.4 billion rose 5.4% and topped the $105.04 billion consensus by 3.2%. On a GAAP basis, CVS earned $1.68 per share, a swing from a $3.13 loss a year ago. That comparison is flattered by the absence of last year's $5.7 billion goodwill impairment, so the adjusted figures are the better guide to the trend. The bigger news came alongside the numbers. Management raised full-year guidance again, set a higher 2027 floor, restarted buybacks and announced plans to split the company in two. The central tension is that the managed-care recovery is running well ahead of plan just as the pharmacy-benefit engine is being guided to a trough year.

The beat came almost entirely from Health Care Benefits. Segment adjusted operating income nearly tripled to $912 million from $314 million. The medical benefit ratio improved 150 basis points to 91.3%, and management said Medicare Advantage is now profitable in 2026, ahead of plan. The quality of that improvement deserves some scrutiny, though not alarm.

• **Reserve releases:** Prior-year reserves developed favorably by $1.3 billion over nine months.
• **Reserve cushion:** Days claims payable ticked up only 0.2 days sequentially to 41.9, suggesting the cushion is not being drawn down to manufacture results.
• **Revenue mix:** Segment revenue grew just 2.4%. Government premiums rose 8.2%, while commercial premiums fell 16.9% after the exit from the individual exchanges. This is margin repair, not volume growth.
• **Charges below the line:** A $193 million Omnicare guarantee charge, worth $0.15 per share, was excluded from adjusted results. It is a reminder that legacy liabilities still sit beneath the headline.

The other two segments tell a more mixed story.

• **Pharmacy & Consumer Wellness:** Adjusted operating income rose 10.6% even as revenue slipped 2.0%. Gross margin expanded to 19.2% from 18.1%, helped by core pharmacy strength and the Rite Aid file acquisitions. However, same-store sales fell 0.6%, and same-store script growth slowed to roughly 4% from about 7% in the first half as Rite Aid share gains began to lap. GLP-1 scripts grew 23%, a useful offset.
• **Health Services:** This is the genuine soft spot. Revenue grew 9.5% on drug mix and brand inflation, but adjusted operating income rose only 2.7%, and adjusted margin narrowed to 3.9% from 4.2% as client price improvements continued to bite.

Guidance carries the forward story. Full-year 2026 adjusted EPS guidance is now at least $8.20, up from $7.90-$8.10. That marks a third consecutive raise and puts the outlook more than $1 above the initial $7.00-$7.20 view. Other elements of the outlook also moved higher:

• **Revenue:** Guidance rose to at least $420 billion.
• **Medical costs:** The MBR outlook moved to the lower half of 89.75% plus or minus 25 basis points.
• **Operating cash flow:** Guidance jumped to at least $15.5 billion from $11.5 billion. Year-to-date cash flow is already $15.3 billion, which implies notable caution for the fourth quarter.
• **2027:** The adjusted EPS floor rose to at least $8.65 from $8.44.
• **Longer-term growth:** Management now expects the high end of its mid-teens EPS growth target through 2028.
• **Capital return:** Leverage reached target ahead of schedule, so repurchases resume this quarter.

The offset is explicit. Health Services adjusted operating income is guided to a floor of at least $7 billion in 2027, framed as trough earnings. Management attributed the decline to lower 340B contribution and Caremark health-plan client attrition, including Aetna PDP actions and a less robust selling season. Management also kept a cautious stance on elevated industry-wide medical cost trend.

The planned separation adds a structural catalyst. Under the plan, CVS Health would hold Aetna, Caremark, Specialty, Oak Street and Signify, while CVS Pharmacy would hold retail, mail, MinuteClinic and Health100. The split is targeted for the first half of 2028 and is intended to be tax-free. Management repeatedly said it was acting from a position of strength. Bears have legitimate ammunition, however:

• **Costs:** The breakup brings dis-synergies, stranded and public-company costs, and one-time expenses.
• **Commercial ties:** CVS Pharmacy will need durable agreements with Caremark and Aetna.
• **Credit ratings:** Rating agencies may assess a standalone managed-care company differently.
• **Timing:** Most details were deferred.

Investors did not enter the report euphoric. Earnings Whispers sentiment remained positive but softened modestly, from 0.408 to 0.357. The stock closed at $91.41 ahead of the release, down 2.5% from the open after the August report. It had spiked to $101 the day after that report and then gave back the move, bottoming at $84.23 on October 1. Shares sit about 3% above their 200-day moving average, roughly mid-range between those extremes. The internal trend readings are mixed, with momentum positive but AVWAP still negative. The market has been reluctant to pay up for successive guidance raises.

The bottom line is that CVS delivered a high-quality managed-care beat and raised its outlook across nearly every major metric. It also handed investors a more complex thesis built on a 2028 breakup and a 2027 Health Services trough. The Aetna turnaround now looks credible, and the cash generation supports renewed buybacks. Whether the stock can hold a post-report move will likely depend on how convincingly management frames the separation costs and the Caremark recovery beyond 2027.